HighTide

HighTide Therapeutics

East Meets West - the Quest for Cure

HighTide Therapeutics

East Meets West - the Quest for Cure

HighTide Therapeutics

East Meets West - the Quest for Cure

HighTide Therapeutics

East Meets West - the Quest for Cure

HighTide Therapeutics

East Meets West - the Quest for Cure

HighTide Therapeutics

East Meets West - the Quest for Cure

HighTide Therapeutics

East Meets West - the Quest for Cure

HighTide Therapeutics

East Meets West - the Quest for Cure

HighTide Therapeutics

East Meets West - the Quest for Cure

HighTide Therapeutics

East Meets West - the Quest for Cure

HighTide Therapeutics Announces Regulatory Approvals For Expanded Clinical Development of HTD1801 Data to be Presented at AASLD 2019 Shows HighTide Lead Compound Improves NASH in Two Animal Models

HighTide Therapeutics and Silexon Tech have Formed a Long-term Strategic Partnership HighTide Therapeutics Announces DMC Approval to Continue with Phase 2a NASH Study of HTD1801

Our Mission

HighTide Therapeutics is dedicated to the discovery and development of innovative therapeutics for people suffering from chronic liver diseases, gastrointestinal diseases and metabolic disorders with large and unsatisfied market needs.

Learn more

Our Pipeline

NAFLD/NASH (Non-Alcoholic Fatty Liver Disease / Non-Alcoholic Steatohepatitis)
More
PSC (Primary Sclerosing Cholangitis)
More

HTD1801

New molecular entity: ionic salt of two active moieties
Lean more
Acute Pancreatitis
More

HTD4010

Peptide analog of RegIII/PAP protein active fragment
Lean more
Inflammatory Bowel Disease (IBD)
More

HTD2802

An innovative fixed dose combination of two known compounds with clear differentiation for unmet clinical needs
Lean more

News & Events

Lean moreHighTide Therapeutics Announces Regulatory Approvals For Expanded Clinical Development of HTD1801
November 19, 2019

Approvals Support Clinical Trials in China and Canada for HTD1801 in Primary Sclerosing Cholangitis
Lean moreData to be Presented at AASLD 2019 Shows HighTide Lead Compound Improves NASH in Two Animal Models
October 10, 2019

SHENZHEN, CHINA and ROCKVILLE, MD, October 10, 2019 — HighTide Therapeutics Inc. (“HighTide”), a clinical-stage biopharmaceutical company, today announced that multiple abstracts for HTD1801...